Deutsche Märkte schließen in 2 Stunden 54 Minuten

Novo Nordisk A/S (NONOF)

Other OTC - Other OTC Verzögerter Preis. Währung in USD
Zur Watchlist hinzufügen
139,00-1,45 (-1,03%)
Börsenschluss: 03:40PM EST

Novo Nordisk A/S

Novo Allé 1
Bagsvaerd 2880
Denmark
45 44 44 88 88
https://www.novonordisk.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter52.696

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Lars Fruergaard JorgensenPres, CEO & Member of Management Board4,57MN/A1966
Mr. Karsten Munk KnudsenExec. VP, CFO & Member of the Management Board1,75MN/A1971
Mr. Henrik Ehlers WulffExec. VP, Head of Product Supply, Quality & IT and Member of the Management Board1,84MN/A1970
Ms. Camilla SylvestExec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board1,75MN/A1972
Dr. Martin Holst LangeExec. VP, Head of Devel. & Member of the Management Board1,23MN/A1970
Ms. Monique CarterExec. VP, Head of People & Organisation and Member of Management Board1,34MN/A1973
Dr. Marcus Schindler Ph.D.EVP, Head of Research & Early Devel., Chief Scientific Officer & Member of the Management Board1,23MN/A1966
Mr. Maziar Mike DoustdarExec. VP, Head of International Operations & Member of the Management BoardN/AN/A1970
Mr. Douglas J. LangaExec. VP, Head of North America Operations & Member of Management BoardN/AN/A1966
Mr. Ludovic HelfgottExec. VP, Head of Rare Disease & Member of Management BoardN/AN/A1974
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Corporate Governance

Novo Nordisk A/Ss ISS Governance QualityScore, Stand 28. Januar 2023, lautet 2. Die grundlegenden Scores sind Audit: 3, Vorstand: 3, Shareholderrechte: 10, Kompensation: 1.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.